duoogle Mizuho started coverage of Medpace ( NASDAQ: MEDP ) with a buy rating, citing its earnings growth potential. The investment bank said it sees the company “bucking the biotech trend” with its industry-leading revenue and EPS growth over the past five years. Mizuho also highlighted the company’s “expertise in serving small to mid-size biotechnology companies, and solid balance sheet and cash flow which provide financial flexibility.
” It added the company’s earnings growth was “entirely organic and unadjusted, in contrast to the peer group” and that there was “more upside potential to EPS than downside risk.” Mizuho set its price target for Medpace at $435. More on Medpace Medpace Holdings, Inc.
(MEDP) Q1 2024 Earnings Call Transcript Medpace Holdings, Inc. 2024 Q1 - Results - Earnings Call Presentation Medpace: Exceptional Performance, Almost Fully Priced In Medpace raised to Buy at Jefferies after Q1 earnings beat Medpace GAAP EPS of $3.20 beats by $0.
73, revenue of $511M misses by $1M.
